| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 08/05/2024 | 22:17 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 18/04/2024 | 12:30 | GlobeNewswire Inc. | Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 27/02/2024 | 22:02 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 16/02/2024 | 22:46 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 09/02/2024 | 15:00 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 09/02/2024 | 01:19 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 24/01/2024 | 14:30 | PR Newswire (US) | Kuehn Law Encourages MDC, WAVD, NS and CERE Investors to Contact Law Firm | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 18/01/2024 | 13:44 | Edgar (US Regulatory) | Form DEFM14A - Definitive proxy statement relating to merger or acquisition | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 18/01/2024 | 13:19 | Edgar (US Regulatory) | Form PRER14A - Preliminary Proxy Soliciting materials | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 05/01/2024 | 23:13 | Edgar (US Regulatory) | Form PREM14A - Preliminary proxy statements relating to merger or acquisition | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 03/01/2024 | 00:10 | PR Newswire (US) | Kuehn Law Encourages CERE, HA, IMGN, and WAVD Investors to Contact Law Firm | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 26/12/2023 | 23:03 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 08/12/2023 | 23:00 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 08/12/2023 | 12:23 | IH Market News | Apple Boosts Vietnam Production, Broadcom Revenue Miss, Stellantis Job Cuts – Latest Updates | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 07/12/2023 | 12:23 | IH Market News | Alphabet Unveils Advanced AI Model, AMD Expects $45 Billion AI Market, Chevron’s $19.5B Investment Plans, BMY Increases Dividend, and More | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 07/12/2023 | 05:24 | PR Newswire (US) | CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding AbbVie's Proposed Acquisition of Cerevel Therapeutics | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 06/12/2023 | 22:30 | PR Newswire (US) | AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 29/11/2023 | 12:30 | GlobeNewswire Inc. | Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 08/11/2023 | 12:30 | GlobeNewswire Inc. | Cerevel Therapeutics to Present at Upcoming Investor Conferences | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 01/11/2023 | 11:30 | GlobeNewswire Inc. | Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 13/10/2023 | 12:30 | GlobeNewswire Inc. | Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023 | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 12/10/2023 | 22:16 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 12/10/2023 | 04:45 | GlobeNewswire Inc. | Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 11/10/2023 | 22:01 | GlobeNewswire Inc. | Cerevel Therapeutics Announces Proposed Public Offering of Common Stock | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 29/08/2023 | 12:30 | GlobeNewswire Inc. | Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 02/08/2023 | 12:30 | GlobeNewswire Inc. | Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 05/07/2023 | 12:30 | GlobeNewswire Inc. | Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023 | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 29/06/2023 | 01:00 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 15/06/2023 | 22:37 | Edgar (US Regulatory) | Report of Proposed Sale of Securities (144) | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |
| 15/06/2023 | 12:30 | GlobeNewswire Inc. | Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer | NASDAQ:CERE | Cerevel Therapeutics Holdings Inc |